Answers are grounded in this paper and cite their sources.
Compared with chemotherapy, either pembrolizumab plus chemotherapy or pembrolizumab monotherapy is not regarded as a cost-effective strategy for patients with CPS≥1, advanced gastric cancer in the current American and Chinese setting. But pembrolizumab monotherapy for CPS≥10 patients would become a cost-effective option in the American setting.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: